SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease

Ara, 1998, Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Proc. Natl. Acad. Sci. U.S.A., 95, 7659, 10.1073/pnas.95.13.7659

Arai, 1990, Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for Parkinsonism, Brain Res., 515, 57, 10.1016/0006-8993(90)90576-W

Bennett, B.L., Sasaki, D.T., Murray, B.W., O’Leary, E.C., Sakata, S.T., Xu, W., Leisten, J.C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S.S., Manning, A.M., Anderson, 2001. SP600125 an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 98, 13681–13686.

Blanchet, 1998, Chronic exposure to MPTP as a primate model of progressive Parkinsonism: a pilot study with a free radical scavenger, Exp. Neurol., 153, 214, 10.1006/exnr.1998.6906

Davis, 2000, Signal transduction by the JNK group of MAP kinases, Cell, 103, 239, 10.1016/S0092-8674(00)00116-1

Derijard, 1994, JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain, Cell, 76, 1025, 10.1016/0092-8674(94)90380-8

Eberhardt, 2000, Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factoe gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease, J. Neurosci., 20, 9126, 10.1523/JNEUROSCI.20-24-09126.2000

Fall, 1999, Characterization and time-course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells, J. Neurosci. Res., 55, 620, 10.1002/(SICI)1097-4547(19990301)55:5<620::AID-JNR9>3.0.CO;2-S

Gasser, 1998, A susceptibility locus for Parkinson’s disease maps to chromosome 2p13, Nat. Genet., 18, 262, 10.1038/ng0398-262

Haase, 1997, Cellular distribution of c-Jun and c-Fos in rat lung before and after bleomycin induced injury, Virchows. Arch., 431, 441, 10.1007/s004280050121

Hartmann, 2000, Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease, Proc. Natl. Acad. Sci. U.S.A., 97, 2875, 10.1073/pnas.040556597

Hornykiewicz, 1987, Biochemical pathophysiology of Parkinson’s disease, Adv. Neurol., 45, 19

Hsu, 1981, Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures, J. Histochem. Cytochem., 29, 577, 10.1177/29.4.6166661

Jackson-Lewis, 1995, Time course and morphology of dopaminerigic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurodegeneration, 4, 257, 10.1016/1055-8330(95)90015-2

Kyriakis, 1994, The stress-activated protein kinase subfamily of c-Jun kinases, Nature, 369, 156, 10.1038/369156a0

Langston, 1996, The etiology of Parkinson’s disease with emphasis on the MPTP story, Neurology, 47, S153, 10.1212/WNL.47.6_Suppl_3.153S

Langston, 1983, Chronic Parkinsonism in humans due to a product of meperidine–analog synthesis, Science, 219, 979, 10.1126/science.6823561

Leroy, 1998, The ubiquitin pathway in Parkinson’s disease, Nature, 395, 451, 10.1038/26652

Lloyd, 1977, CNS compensation to dopamine neuron loss in Parkinson’s disease, Adv. Exp. Med. Biol., 90, 255, 10.1007/978-1-4684-2511-6_16

Lotharius, 1999, Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons, J. Neurosci., 19, 1284, 10.1523/JNEUROSCI.19-04-01284.1999

Luo, 1998, Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway, J. Biol. Chem., 273, 3756, 10.1074/jbc.273.6.3756

Maroney, 1999, CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults, J. Neurochem., 73, 1901, 10.1046/j.1471-4159.1999.01901.x

Maroney, 1998, Motoneuron apoptosis is blocked by CEP-1347 (KT 7515) a novel inhibitor of the JNK signaling pathway, J. Neurosci., 18, 104, 10.1523/JNEUROSCI.18-01-00104.1998

Marsden, 1977, Success and problems of long-term levodopa therapy in Parkinson’s disease, Lancet, 1, 345, 10.1016/S0140-6736(77)91146-1

Mattson, 2000, Apoptosis in neurodegenerative disorders, Nat. Rev. Mol. Cell. Biol., 1, 120, 10.1038/35040009

Nicholson, 1995, Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis, Nature (London), 376, 37, 10.1038/376037a0

Oertel, 1995, Parkinson’s disease-medical education and psychosocial aspects, Patient Educ. Couns., 26, 71, 10.1016/0738-3991(95)00757-Q

Pakkenberg, 1991, The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method, J. Neurol. Neurosurg. Psychiatry, 54, 30, 10.1136/jnnp.54.1.30

Petroske, 2001, Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment, Neuroscience, 106, 589, 10.1016/S0306-4522(01)00295-0

Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease, Science, 276, 2045, 10.1126/science.276.5321.2045

Quinn, 1998, Classification of fluctuations in patients with Parkinson’s disease, Neurology, 51, S25, 10.1212/WNL.51.2_Suppl_2.S25

Saporito, 1999, CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo, J. Pharmacol. Exp. Ther., 288, 421

Saporito, 1992, Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured mesencephalon: relationship to dopamine uptake affinity and inhibition of mitochondrial respiration, J. Pharmacol. Exp. Ther., 260, 1400

Saporito, 2000, MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo, J. Neurochem., 75, 1200, 10.1046/j.1471-4159.2000.0751200.x

Seniuk, 1990, Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP, Brain Res., 527, 7, 10.1016/0006-8993(90)91055-L

Srinivasan, 1998, In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system, Cell Death Differ., 5, 1004, 10.1038/sj.cdd.4400449

Tatton, 1997, In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining, Neuroscience, 77, 1037, 10.1016/S0306-4522(96)00545-3

Tewari, 1995, Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase, Cell, 81, 801, 10.1016/0092-8674(95)90541-3

Tillerson, 2002, Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Exp. Neurol., 178, 80, 10.1006/exnr.2002.8021

Tipton, 1993, Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds, J. Neurochem., 61, 1191, 10.1111/j.1471-4159.1993.tb13610.x

Tolwani, 1999, Experimental models of Parkinson’s disease: insights from many models, Lab. Anim. Sci., 49, 363

West, 1999, Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias, Trends Neurosci., 22, 51, 10.1016/S0166-2236(98)01362-9

Xia, 2001, Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson’s disease, Proc. Natl. Acad. Sci. U.S.A., 98, 10433, 10.1073/pnas.181182298

Yuan, 2000, Apoptosis in the nervous system, Nature, 407, 802, 10.1038/35037739